Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

[1]  Sanjiv J. Shah,et al.  Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. , 2018, JACC. Heart failure.

[2]  S. Solomon,et al.  Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum , 2018, European journal of heart failure.

[3]  Akshay S. Desai,et al.  Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. , 2018, JACC. Heart failure.

[4]  D. Atar,et al.  Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial , 2018, Circulation. Heart failure.

[5]  Sanjiv J. Shah,et al.  The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors , 2017, European journal of heart failure.

[6]  P. Ponikowski,et al.  Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. , 2017, JACC. Heart failure.

[7]  T. Hansen,et al.  Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial , 2017, Diabetes, obesity & metabolism.

[8]  Kunihiro Suzuki,et al.  Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. , 2017, Atherosclerosis.

[9]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[10]  B. Lindman.  The Diabetic Heart Failure With Preserved Ejection Fraction Phenotype: Is it Real and Is It Worth Targeting Therapeutically? , 2017, Circulation.

[11]  C. Bezold,et al.  Diabetes 2030: Insights from Yesterday, Today, and Future Trends , 2017, Population health management.

[12]  R. McKelvie,et al.  Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) , 2017, Circulation.

[13]  Deepak L. Bhatt,et al.  Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. , 2016, American heart journal.

[14]  J. Kostis,et al.  Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review , 2016, Cardiology.

[15]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[16]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[17]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[18]  A. Thorp,et al.  Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome , 2015, Journal of diabetes research.

[19]  Angelo Avogaro,et al.  Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. , 2015, JACC. Heart failure.

[20]  Deepak L. Bhatt,et al.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. , 2014, American heart journal.

[21]  A. Pandey,et al.  Epidemiology of Heart Failure with Preserved Ejection Fraction , 2014, Current Heart Failure Reports.

[22]  B. Borlaug,et al.  The pathophysiology of heart failure with preserved ejection fraction , 2014, Nature Reviews Cardiology.

[23]  L. de las Fuentes,et al.  Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. , 2014, Journal of the American College of Cardiology.

[24]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[25]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[26]  Frank B. Hu,et al.  Globalization of Diabetes , 2011, Diabetes Care.

[27]  B. Bozkurt,et al.  Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. , 2010, The American journal of cardiology.

[28]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[29]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[30]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[31]  N. Lamblin,et al.  Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.